The United States is the company's biggest market accounting for 47 per cent of total revenue, followed by India ...

The company's India business, comprising both formulations and consumer wellness divisions, contributed 38 per cent of ...

Zydus Lifesciences Q3 profit rises 30% to Rs 1,023 crore, driven by strong US and domestic market sales. Revenue also ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

Zydus Lifesciences Limited reports 30% profit increase, driven by US formulations business, with strong financial position ...

Pharma stocks tumbled as the Nifty Pharma index dropped two percent, with Alkem, Ipca, and Divi’s Labs leading losses.

Developed by the researchers at the Zydus Research Centre, the biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name, Exemptia to treat ...

AI’s role in healthcare evolved significantly in 2024. Rather than generic AI solutions, startups focused on specialized, ...

The main industry in which Zydus Lifesciences Ltd operates is Pharmaceuticals - Indian - Bulk Drugs & Formln. Auditor/Auditors for Zydus Lifesciences Ltd is/are Deloitte Haskins & Sells LLP.

Shares of Abbott India surged 5.60% higher at ₹27,605.45 on the BSE on Tuesday. The pharma stock reacted positively to the ...